Removing Brain Chemical Helps Reduce Body Fat In Genetically Obese Mice

December 06, 1996

Mice with a mutation that makes them grossly overweight can be induced to be only pleasingly plump, if they are genetically engineered to lack a certain neurotransmitter. Researchers at the University of Washington hope their findings will provide an important clue for future development of drugs that would suppress the same brain chemical and achieve the same effect in obese humans.

The study, by Drs. Jay C. Erickson, Gunther Hollopeter and Richard D. Palmiter of the UW School of Medicine's Department of Biochemistry, is published in the Dec. 6 issue of the journal Science.

The researchers used a strain of mice that lack leptin, a hormone normally released by fat cells that acts in the brain to suppress the urge to eat and stimulate metabolism. Without leptin, the mice have nothing to curb their appetites; the brain mistakenly thinks the body is starving. The animals become morbidly obese and suffer the ill effects of overweight. But until now, exactly how the brain triggers these effects has been a mystery.

The UW scientists suspected that excessive production of a neurotransmitter called neuropeptide Y (NPY) caused the leptin-deficient mice to overeat and burn fewer calories than normal mice. To test their premise, they genetically engineered mice that lack not only leptin, but also NPY.

Compared to their morbidly obese cousins, the mice lacking NPY become only half as fat. They eat less (although offered the same amount of food), have a higher metabolic rate, have only half as much fat in their "fat pads," and, while insulin-resistant, develop a less severe form of diabetes.

"If what goes on in these mice is similar to what happens in humans," said Erickson, "it suggests that excess NPY may contribute to a slower metabolic rate and an increased drive to eat."

Erickson, a third-year medical student who has a Ph.D in biochemistry from the UW, noted that the study targeted only one form of genetically induced obesity, caused by the inability to produce leptin. It did not look at dietary-induced obesity or other genetic forms of obesity.

Since the suppression of NPY did not result in normal-weight mice, said Erickson, other neurotransmitters must be responsible for the remaining tendency to obesity. "Another goal is to identify those elements," he said. "Many labs are working on this."
-end-
Dr. Erickson, first author, can be reached by pager at (206) 559-2097.

Dr. Palmiter, principal investigator, is out of the country and cannot be reached until Dec. 9, at (206) 543-6064 or (206) 543-6090.

University of Washington

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.